KYTX net incomeQ2 2026-$38.32M
KYTX net income was -$38.32M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$42.08M a year earlier. For the full fiscal 2025 it was -$161.31M, compared with -$127.48M in fiscal 2024.
Kyverna Therapeutics Inc. (KYTX) financials
For the twelve months ended Jun 30, 2026, Kyverna Therapeutics Inc. reported -$152.64M of net income.
- Net income, TTM
- -$152.64M
- EPS, diluted, TTM
- -$2.93
- Cash
- $31.81M
- Total debt
- $24.88M
- Market cap
- $319.7M
FY2023FY2025
FY2023FY2025
KYTX revenue and earnings growth
KYTX EPSQ2 2026-$0.63
KYTX diluted EPS was -$0.63 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$3.64, compared with -$3.33 in fiscal 2024.
KYTX free cash flowQ4 2025-$33.53M
KYTX free cash flow was -$33.53M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$37.59M a year earlier. For the full fiscal 2025 it was -$153.72M, compared with -$116.45M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Research and development | $133.72M | $112.47M | $49.92M |
| Selling, general and admin | $36.11M | $30.13M | $12.48M |
| Operating income | -$169.83M | -$142.60M | -$62.41M |
| Interest expense | $489.0K | $142.0K | $187.0K |
| Income tax | $0 | $0 | $0 |
| Net income | -$161.31M | -$127.48M | -$60.37M |
| EPS, basic | -$3.64 | -$3.33 | -$89.61 |
| EPS, diluted | -$3.64 | -$3.33 | -$89.61 |
| Diluted shares | 44.3M | 38.3M | 673,622 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $124.09M | $96.62M | $34.65M |
| Short-term investments | $155.16M | $189.36M | $22.90M |
| Current assets | $282.95M | $290.60M | $60.66M |
| Total assets | $293.83M | $304.64M | $75.19M |
| Current liabilities | $36.49M | $33.76M | $19.86M |
| Long-term debt | $24.74M | - | - |
| Total debt | $24.74M | - | - |
| Total liabilities | $61.55M | $38.06M | $26.02M |
| Shareholders' equity | $232.28M | $266.59M | -$13.14M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$153.71M | -$114.25M | -$52.41M |
| Capital expenditures | $5.0K | $2.21M | $621.0K |
| Free cash flow | -$153.72M | -$116.45M | -$53.03M |
| Investing cash flow | $40.02M | -$160.90M | -$8.79M |
| Financing cash flow | $141.17M | $337.11M | $58.12M |
| Stock-based compensation | $10.08M | $8.36M | $2.22M |
| Depreciation and amortization | $1.80M | $2.13M | $1.71M |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $24.79M | $30.07M | $30.01M | $30.46M | $35.82M | $37.43M | $33.48M | $29.19M | $27.32M | $22.48M | $17.16M | $13.64M |
| Selling, general and admin | $14.77M | $11.29M | $9.27M | $8.27M | $8.59M | $9.97M | $7.56M | $9.58M | $6.11M | $6.88M | $4.21M | $2.64M |
| Operating income | -$39.56M | -$41.37M | -$39.28M | -$38.73M | -$44.41M | -$47.41M | -$41.04M | -$38.77M | -$33.44M | -$29.36M | -$21.38M | -$16.28M |
| Interest expense | $674.0K | $667.0K | $444.0K | $7.0K | $14.0K | $25.0K | $27.0K | $32.0K | $39.0K | $44.0K | $47.0K | $50.0K |
| Net income | -$38.32M | -$39.73M | -$37.80M | -$36.79M | -$42.08M | -$44.63M | -$37.49M | -$34.49M | -$28.80M | -$26.69M | -$20.67M | -$15.46M |
| EPS, basic | -$0.63 | -$0.66 | -$0.79 | -$0.85 | -$0.97 | -$1.03 | - | -$0.80 | -$0.67 | -$1.12 | - | -$23.27 |
| EPS, diluted | -$0.63 | -$0.66 | -$0.79 | -$0.85 | -$0.97 | -$1.03 | - | -$0.80 | -$0.67 | -$1.12 | - | -$23.27 |
| Diluted shares | 60.9M | 60.4M | - | 43.4M | 43.2M | 43.2M | - | 43.2M | 43.1M | 23.8M | - | 664,656 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $31.81M | $32.19M | $124.09M | $34.16M | $53.44M | $56.87M | $96.62M | $104.66M | $131.62M | $224.29M | $34.65M | $22.97M |
| Short-term investments | $167.62M | $204.25M | $155.16M | $136.97M | $158.24M | $185.78M | $189.36M | $216.92M | $214.62M | $145.51M | $22.90M | - |
| Current assets | $206.54M | $241.73M | $282.95M | $174.93M | $214.33M | $247.65M | $290.60M | $325.37M | $348.82M | $375.49M | $60.66M | - |
| Total assets | $219.82M | $257.02M | $293.83M | $187.16M | $226.51M | $260.65M | $304.64M | $339.20M | $363.12M | $389.98M | $75.19M | - |
| Current liabilities | $22.80M | $29.67M | $36.49M | $33.87M | $39.79M | $33.29M | $33.76M | $30.98M | $23.48M | $21.86M | $19.86M | - |
| Long-term debt | $24.88M | - | $24.74M | - | - | - | - | - | - | - | - | - |
| Total debt | $24.88M | - | $24.74M | - | - | - | - | - | - | - | - | - |
| Total liabilities | $54.27M | $61.44M | $61.55M | $35.21M | $42.13M | $36.65M | $38.06M | $36.49M | $29.61M | $28.99M | $26.02M | - |
| Shareholders' equity | $165.55M | $195.58M | $232.28M | $151.95M | $184.38M | $224.01M | $266.59M | $302.71M | $333.51M | $360.99M | -$13.14M | -$111.81M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$40.31M | -$41.60M | -$33.53M | -$43.32M | -$31.95M | -$44.91M | -$37.06M | -$27.49M | -$24.18M | -$25.52M | -$18.56M | -$11.13M |
| Capital expenditures | - | - | -$1.0K | $2.0K | $4.0K | $0 | $532.0K | $102.0K | $1.03M | $543.0K | $334.0K | $256.0K |
| Free cash flow | - | - | -$33.53M | -$43.32M | -$31.95M | -$44.91M | -$37.59M | -$27.59M | -$25.20M | -$26.07M | -$18.90M | -$11.39M |
| Investing cash flow | $36.13M | -$50.20M | -$17.29M | $22.56M | $29.17M | $5.58M | $29.22M | $676.0K | -$67.92M | -$122.88M | $31.68M | -$54.12M |
| Financing cash flow | $3.79M | -$101.0K | $140.74M | $1.49M | -$649.0K | -$414.0K | -$215.0K | -$152.0K | -$569.0K | $338.05M | -$1.43M | $34.79M |
| Stock-based compensation | $3.51M | $3.17M | $2.70M | $2.70M | $2.52M | $2.16M | $1.38M | $3.41M | $1.28M | $2.28M | $784.0K | $521.0K |
| Depreciation and amortization | $300.0K | $351.0K | $368.0K | $300.0K | $300.0K | $501.0K | $563.0K | $300.0K | $300.0K | $482.0K | $462.0K | $200.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 9.06 | 8.15 | 7.75 | 5.16 | 5.39 | 7.44 | 8.61 | 10.50 | 14.86 | 17.17 | 3.05 | - |
| Debt to equity | 0.15 | - | 0.11 | - | - | - | - | - | - | - | - | - |
Source: XBRL data Kyverna Therapeutics Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
KYTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| KYTX | - | - | -$152.64M | - | $319.7M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
KYTX FAQ
5 questionsIs KYTX profitable?
No. Kyverna Therapeutics Inc. reported a net loss of $152.64M for the twelve months ended Jun 30, 2026.How much cash and debt does KYTX have?
Kyverna Therapeutics Inc. reported $31.81M in cash and cash equivalents and $24.88M of debt on its most recent balance sheet in SEC filings.What is KYTX earnings per share?
Diluted earnings per share were -$2.93 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did KYTX last report financial results?
The latest statements here come from Kyverna Therapeutics Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this KYTX financial data come from?
Quantisnow builds these statements from the structured XBRL data Kyverna Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.